argenx SE
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
17 sep 2014 - 07:02
Statutaire naam
argenx SE
Titel
arGEN-X' core patents protecting lead clinical candidates ARGX-110 and ARGX-111 receive accelerated grant in the United States
Bericht
17 September 2014
Breda, the Netherlands / Ghent, Belgium - arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, is pleased to announce the grant of key patents in the United States relating to its two lead clinical candidates ARGX-110 and ARGX-111.
The US Patent & Trademark Office (USPTO) granted composition-of-matter claims relating to ARGX-110, a novel SIMPLE Antibody(TM) product targeting human CD70. The issued patent (US 8,834,882) was examined by the USPTO's Track 1 Prioritized Examination Program leading to a patent grant within ten months of filing. This grant is in addition to the recent grant of an arGEN-X patent (US 8,637,027) relating to ARGX-111, a proprietary SIMPLE Antibody(TM) targeting human c-Met. Both patent rights are projected to expire in 2031-2032 but are eligible for up to an additional five years of Patent Term Extension for marketing delays caused by necessary clinical trials and FDA regulatory review.
Gerelateerde downloads
Datum laatste update: 01 september 2024